Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Tivic Health Systems, Inc. (Nasdaq: TIVC) generates news that reflects its evolution into a diversified immunotherapeutics and health technology company. This page aggregates coverage of Tivic’s progress in biologics, bioelectronic medicine and contract development and manufacturing, giving investors and observers a single place to review its latest corporate announcements.
Much of Tivic’s recent news flow centers on Entolimod™, its lead Toll-like Receptor 5 (TLR5) agonist drug candidate for acute radiation syndrome (ARS) and related conditions. Articles highlight milestones such as cell line verification, large-scale manufacturing runs, and steps toward current Good Manufacturing Practice (cGMP) production in preparation for a potential Biologics License Application (BLA). Releases also discuss Entolimod’s Fast Track and Orphan Drug designations, its development under the FDA’s Animal Rule, and animal data showing effects on survival, gastrointestinal recovery and hematopoiesis after radiation exposure.
Another major theme in Tivic news is its acquisition of manufacturing and development assets and the launch of Velocity Bioworks™, a wholly owned CDMO subsidiary. Coverage describes how Velocity Bioworks is expected to support Tivic’s own biologics pipeline and offer development and manufacturing services to third-party biotech companies, creating additional revenue opportunities and reducing reliance on external manufacturers.
Visitors will also find updates on Tivic’s bioelectronic program, including results from a clinical optimization trial of non-invasive cervical vagus nerve stimulation conducted with The Feinstein Institutes for Medical Research at Northwell Health. These stories detail how personalized stimulation parameters can influence autonomic measures such as heart rate variability.
In addition, Tivic regularly reports on its interactions with government and industry stakeholders, including BARDA TechWatch meetings, participation in the Military Health System Research Symposium, and conference presentations outlining its strategic transformation. For investors tracking TIVC, this news feed offers a consolidated view of clinical, manufacturing, partnership and capital markets developments.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health technology firm focused on bioelectronic medicine, will report its financial results for Q2 2022 on August 15, 2022. The earnings call will begin at 1:30 PM PT / 4:30 PM ET, with a conference call for investors and analysts available via toll-free and international lines. Shareholders can also submit questions by August 11, 2022, at ir@tivichealth.com. More information can be found at Tivic Health's website.
Tivic Health Systems, Inc. (TIVC) announced that its ClearUP® Sinus Pain Relief device has been awarded the Most Innovative Sinus Relief Solution for 2022 by Global Health & Pharma. This recognition marks the second consecutive year for ClearUP, which is FDA-cleared and clinically proven to alleviate sinus pain and congestion. The company aims to further develop bioelectronic treatments for various conditions, reflecting a shift towards non-invasive medical solutions. Recent accolades enhance Tivic's visibility in the health tech space, signaling strong market potential.
Tivic Health Systems (Nasdaq: TIVC) announced its Annual General Meeting of Shareholders to be held virtually on June 14, 2022, at 10:00 AM PDT. This format aims to ensure accessibility for all shareholders. Related documents and information can be found on Tivic Health's website and the SEC's website. The company specializes in non-invasive bioelectronic treatments for inflammation and related conditions. Forward-looking statements in the release highlight inherent risks and uncertainties affecting future performance.
Summary not available.
Tivic Health Systems, Inc. (TIVC) reported a strong first quarter 2022 with a 33% increase in net revenue to $428K compared to $323K in Q1 2021. Notably, gross profit surged 219% to $70K, driven by a 77% growth in direct-to-consumer unit sales. Overall unit sales rose by 28%, aided by the termination of less profitable retail arrangements. However, total expenses rose significantly, including $684K in sales and marketing, reflecting increased advertising and e-commerce efforts. Cash reserves stood at approximately $10.8 million as of March 31, 2022.
Jennifer Ernst, CEO of Tivic Health, will speak at FORTUNE Brainstorm Health on May 11, participating in a panel titled Driving Digital Health: Where Wearables Are Headed Next. The event, held in Los Angeles on May 10-11, 2022, focuses on the intersections of health care and technology, highlighting innovations that enhance health outcomes. Ernst's recent accolades include recognition as one of the Inc 100 Female Founders and a leader in Consumer Healthcare.
For more on Tivic Health, visit tivichealth.com.
Tivic Health Systems, Inc. (Nasdaq: TIVC) will report its Q1 2022 financial results on May 16, 2022, at 1:30 pm PT (4:30 pm ET) via conference call and webcast. Investors can access the call at this link. The company focuses on non-invasive bioelectronic treatments for inflammation and related conditions. For further information, visit Tivic Health's website.
Tivic Health® Systems, Inc. (Nasdaq: TIVC) announced its fourth quarter 2021 financial results and year-end shareholder update via conference call on April 19, 2022. The call is scheduled for 2:00 pm PT / 5:00 pm ET, providing insights into the company’s performance in the bioelectronic medicine sector. Interested participants can join by calling the toll-free number 888-506-0062 or the international number 973-528-0011 with the access code 689084. Tivic Health focuses on non-invasive treatments for inflammation and related conditions.
Tivic Health Systems (Nasdaq: TIVC) announced key executive appointments, effective April 1, 2022. Veronica Cai becomes Chief Financial Officer, succeeding Briana Benz. Ryan Sabia is promoted to Chief Operating Officer, and Sanjay Ahuja joins as Senior Vice President, Quality Assurance & Regulatory Affairs. Cai brings 25 years of finance experience, while Ahuja has over 25 years in regulatory affairs. CEO Jennifer Ernst emphasizes that their expertise aligns with the company's growth strategy in bioelectronic medicine.
Summary not available.